Insulin aspart (Fiasp) vs THDB0206
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
Insulin aspart (Fiasp)
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07652528 (registry estimate)
No aligned efficacy figure on record for this race.
THDB0206
Developed by Adocia and partners
NCT05834868 · Phase 3 · completed
The study was randomized and actively controlled with insulin lispro, but it was open-label and used change in HbA1c as its primary, surrogate endpoint rather than a hard clinical outcome. Registry results are not posted; the sponsors (Adocia and Tonghua Dongbao) announced positive topline results versus Humalog in July 2025, so the result rests on a company announcement.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin aspart (Fiasp) | THDB0206 |
|---|---|---|
| HbA1c, change | 6.6% vs 6.6%vs NovoRapidNCT018191292 other results
| —Not posted · NCT05834868 |
| Body weight, change (kg) | 1.2 vs 1.1vs NovoRapidNCT03268005 | —Not posted · NCT05834868 |
| HbA1c below 7% | —Not reported | —Not posted · NCT05834868 |
| Fasting plasma glucose, change | 0.6 vs 0.7vs NovoRapidNCT03268005 | —Not posted · NCT05834868 |
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT05834868 |
HbA1c, change
- Insulin aspart (Fiasp)
- 6.6% vs 6.6%vs NovoRapidNCT01819129
2 other results
- -0.1% vs -0.1% NCT03268005
- 6.8% vs 7.7% NCT01850615
- THDB0206
- —Not posted · NCT05834868
Body weight, change (kg)
- Insulin aspart (Fiasp)
- 1.2 vs 1.1vs NovoRapidNCT03268005
- THDB0206
- —Not posted · NCT05834868
HbA1c below 7%
- Insulin aspart (Fiasp)
- —Not reported
- THDB0206
- —Not posted · NCT05834868
Fasting plasma glucose, change
- Insulin aspart (Fiasp)
- 0.6 vs 0.7vs NovoRapidNCT03268005
- THDB0206
- —Not posted · NCT05834868
3-point MACE (% with event)
- Insulin aspart (Fiasp)
- —Not reported
- THDB0206
- —Not posted · NCT05834868
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
THDB0206: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Insulin aspart (Fiasp): 4 of 4 rows · THDB0206: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Insulin aspart (Fiasp) |
|---|---|
| Dropout rate | 12.8%a NCT01819129 · Phase 3 show 2 more results7.8% NCT01850615 · Phase 3 · combination 2.7% NCT03268005 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 0.3%a NCT01819129 · Phase 3 show 2 more results1.7% NCT01850615 · Phase 3 · combination — NCT03268005 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 4.4%a NCT01819129 · Phase 3 show 2 more results5.2% NCT01850615 · Phase 3 · combination 7% NCT03268005 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | a urinary tract infection 5.9% nasopharyngitis 5% upper respiratory tract infection 4.7% NCT01819129 · Phase 3 show 2 more resultsdiarrhoea 1.7% NCT01850615 · Phase 3 · combination nasopharyngitis 5.9% NCT03268005 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Insulin aspart (Fiasp)
show 2 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin aspart (Fiasp)'s landscape · THDB0206's landscape